Search for:

Click to read

Digital healthcare, a globally booming market, has been catalyzed by the events of COVID-19. In Asia Pacific, in particular, a rapidly expanding population, an empowered and tech-savvy middle class and physician shortage has created the perfect conditions for digital health innovation.

A new era of digital healthcare innovation looms on the horizon where there is now greater imperative to develop future-proof digital health solutions and systems in a “next-generation” ecosystem that channels hybridity and multi-functionality.

Baker McKenzie’s newest report, Hyper-Hybridity: Defining a New Era of Digital Health Innovation in Asia Pacific, explores challenges, priorities and potential collaboration pathways in digital health from the perspective of over 700 professionals in the ecosystem from three main groups — healthcare and life sciences organizations, technology companies and investors. The report explores:

  • Digital health technologies in development and priorities for next-generation solutions
  • Opportunities for financial and strategic investors in digital health in the region
  • How ecosystems players can effectively join forces to overcome barriers to innovation
  • Legal considerations associated with accelerating innovation through collaborations and partnerships

Key findings

  • 83% of digital health players say there is rising market pressure to build new digital health solutions and systems.
  • 72% of digital health players believe a radical rethink of how innovation is organized, funded and scaled is required to meet demand for new solutions.
  • 74% of digital health players suggest greater collaboration across the healthcare ecosystem would significantly accelerate progress.
  • 78% of healthcare and life sciences companies report concern that technology organizations push a commercial agenda over healthcare excellence.
  • 71% of technology players indicate that healthcare companies often lack the tech know-how to operationalize new solutions.
  • Investors surveyed intend to direct USD 22 billion of global funding into digital health innovation in Asia Pacific.
Author

Elisabeth White is a partner in Baker McKenzie's Sydney office. Elisabeth has over 15 years' experience as an intellectual property and regulatory advisor, focusing upon IP protection and enforcement with a particular emphasis on regulated industries and related disputes. Elisabeth is described in Asia Pacific Legal 500 as providing “decisive expert opinion and a pragmatic approach”. She has been featured in Best Lawyers - Intellectual Property listed annually since 2013.

Author

Vanina Caniza is a partner in Baker McKenzie’s Buenos Aires office and the Global Chair of the Healthcare & Life Sciences Group. She advises a range of multinational, Latin America and Argentine clients in a variety of corporate and commercial law matters, with extensive experience in corporate compliance, commercial agreements, mergers & acquisitions and regulatory advice. Vanina has extensive knowledge in the pharmaceutical, biotech and medical device sectors. She completed postgraduate courses on Biotechnology at Universidad Torcuato di Tella (Buenos Aires) and on Health Law at Universidad de Buenos Aires. She was previously the Latin America Leader of the Healthcare & Life Sciences Group and also sits on the Steering Committee of the Firm’s Latin America Corporate Compliance Group. She is currently a professor in the CEC Compliance & Ethics Certification (AAEC-UCEMA).

Author

Dr. Isabella Liu is the head of the Firm's Asia Pacific Healthcare Industry Group. She advises clients on matters relating to the creation, exploitation and protection of IP rights. She is also responsible for the local IP Group’s China and Hong Kong patent prosecution matters. Dr. Liu is ranked as a leading lawyer in her field by top legal directories such as Chambers Asia Pacific for the Life Sciences category and IAM Patent. She has been complimented by clients that she possesses “a superb ability to understand the most complex technologies” and was noted for "advis[ing] in a way that is very commercial and strategic."

Author

Kate Jefferson joined Baker McKenzie’s Sydney office in 2005 and worked in the Firm’s New York office in 2007 and 2008. Kate also undertook a four month secondment to at a global investment bank. Kate previously worked for Herbert Smith Freehills from 2001 to 2005 and as a management consultant to the London Stock Exchange from 2000 to 2001.

Author

Ren Jun is an associate principal of Baker & McKenzie.Wong & Leow. Ren Jun extensively represents local and international intellectual property-intensive clients in both contentious and non-contentious IP matters, such as anti-counterfeiting; civil and criminal litigation; commercial issues; regulatory clearance; and advertising laws. Ren Jun also advises on a wide range of issues relating to the healthcare industries. These include regulatory compliance in respect of drugs, medical devices, clinical trials, health supplements and cosmetics; product liability and recall; and anti-corruption. Ren Jun is currently a member of the Firm's Asia Pacific Healthcare ASEAN Economic Community; Product Liability and Regulatory Sub-Committees.

Author

Toby Patten is a partner in Baker McKenzie's Technology and Healthcare teams in Melbourne. He joined the Firm in March 2005.

Author

Tracy Wut is a partner in Baker McKenzie's Hong Kong office. She is experienced in mergers and acquisitions and foreign direct investments in China. She regularly acts for clients in complex cross-border transactions, in particular in the pharmaceuticals and healthcare sector, and navigates clients through various issues relating to investments in China. She has been recommended as a leading lawyer in Corporate/M&A by Chambers Global, Corporate/M&A and Life Sciences by Chambers Asia and M&A and private equity by IFLR1000. She is the co-head of the Pharmaceuticals and Healthcare Industry Group in China and Hong Kong.

Author

Yee Chung Seck leads the Firm’s Mergers & Acquisitions, IT/C, Pharmaceutical and Healthcare Practices in Vietnam. Chambers Global (2014, 2013) and Chamber Asia (from 2010 to 2015) rank him as a leading lawyer in the field of Corporate M&A and TMT in Vietnam. He is a member of the Singapore Bar Association and serves as vice president of the Singapore Business Group. He also serves as AmCham's IT/C Sub-Committee Co-Chair. Mr. Seck is fluent in English and conversational in Mandarin.

Author

Ryosuke Tateishi is a member of the Tokyo Corporate/M&A and Dispute Resolution groups. Prior to joining https://www.bakermckenzie.com/enBaker McKenzie, Ryosuke worked for Sumitomo Corporation. He is a member of the Daini Tokyo Bar Association and has been a METI-registered management consultant since 2003.

Author

Peerapan Tungsuwan is a corporate and M&A partner in Bangkok office with specialties in highly regulated industries, including the healthcare industry. She is currently Chair of the AEC Healthcare Harmonization Sub-committee of Baker McKenzie's Asia Pacific Healthcare Industry Group, of which she was head from 2007-2013. Within the Bangkok office, she heads the Healthcare Industry and Natural Resources Groups and co-leads the Mergers & Acquisitions practice group and Japan Advisory Group.

Author

Cahyani Endahayu is a partner in the Mergers & Acquisitions Practice Group. Her work includes handling the corporate/licensing, compliance and day-to-day work of several of the Firm’s major clients and providing corporate, compliance and advisory support services to other clients in relation to corporate/commercial issues. She has advised a wide range of domestic and international clients across various industry sectors, including pharmaceutical and retail/trading.

Author

Maria Christina Macasaet-Acaban is a partner, and the head of the Corporate & Commercial Practice Group, the Healthcare Industry Group, and the Competition Focus Group, in Quisumbing Torres, a member firm of Baker & McKenzie International. She is a member of Baker & McKenzie International's Asia Pacific Healthcare Steering Committee, and the Asia Pacific Competition Steering Committee. She has 19 years of experience advising and representing multinational corporations on domestic and cross-border transactions.

Author

Denis Segota is a partner in the Corporate & Securities Practice Group and a member of the Life Sciences Industry Group at Baker McKenzie in New York. Denis has over 20 years of experience in counselling clients in the life science industry. His clients range from early stage start-ups, life science venture and other private equity funds to multinational pharmaceutical companies. Denis assists companies with complex joint ventures, strategic alliances, licensing, and other partnering arrangements promoting the research, development, and commercialization of new products.

Author

Derek Liu is a partner in Baker McKenzie’s San Francisco office. Derek handles mergers and acquisitions, and other complex corporate transactions, and has signed transactions with an aggregate transaction value of more than USD 100 billion. Prior to joining Baker McKenzie, Derek practiced at two top-tier firms in San Francisco and New York.

Author

Jane E. Hobson is a partner in Baker Mckenzie's London office. She works in the Firm's London Corporate group, is a member of the Global M&A Practice Group, and focuses on cross-border mergers and acquisitions, licensing transactions and joint ventures in the pharmaceutical and healthcare sector.

Author

Oren Livne is a partner in the Corporate & Securities Practice Group and the Life Sciences Industry Group. Prior to beginning his law career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Author

Kevin Wang heads the Corporate/M&A and Healthcare practices of Baker McKenzie's Taipei office. With more than 25 years of legal experience, he provides strategic advice on large and complex deals as well as international trade, general corporate and healthcare industry issues.

Author

Ben McLaughlin is the chair of the Global Healthcare Industry Group and a partner in Baker McKenzie's Sydney office. He has over 25 years' experience in advising leading Australian and international public companies on mergers and acquisitions (M&A) and equity capital markets. Ben conceptualized the Baker McKenzie Healthcare MapApp, an acclaimed mobile application that enables clients to access over 1,000 pages of legal summaries. He has been recognized by Chambers for his work in Australian and international M&A matters, as well as in pharmaceuticals and life sciences. Ben is admitted to practice law in Australia and the US, and is an adjunct member of the Faculty of Law at the University of Sydney.